<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247819</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-IRP-148</org_study_id>
    <nct_id>NCT00247819</nct_id>
  </id_info>
  <brief_title>The Genetic Basis for Vulnerability to Substance Abuse</brief_title>
  <official_title>Allelic Linkage in Substance Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      This investigation seeks to better define the genetic basis for vulnerability to substance
      abuse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been
      putatively linked to the development of substance abuse, alcohol abuse, and alcoholism.
      Identification of specific vulnerability-association alleles for receptors, other molecules
      within the reward mediating system, and other genes that may predispose individuals to the
      development of such disorders is the goal of the study.

      This investigation will help elucidate the genetic underpinnings of substance abuse,
      potentially leading to the improved methods to diagnose those at risk and to help develop
      better therapeutic interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1992</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Substance Abuse</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Substance abusers

          -  Allow for blood draw

        Exclusion Criteria:

          -  Cognitively impaired
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Uhl, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute on Drug Abuse</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Noble EP, Blum K, Khalsa ME, Ritchie T, Montgomery A, Wood RC, Fitch RJ, Ozkaragoz T, Sheridan PJ, Anglin MD, et al. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend. 1993 Oct;33(3):271-85. Erratum in: Drug Alcohol Depend 1993 Dec;34(1):83-4.</citation>
    <PMID>8261891</PMID>
  </reference>
  <reference>
    <citation>Clark CJ, Downie CC. A method for the rapid determination of the number of patients to include in a controlled clinical trial. Lancet. 1966 Dec 17;2(7477):1357-8.</citation>
    <PMID>4162809</PMID>
  </reference>
  <reference>
    <citation>Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet. 1989 Nov;45(5):778-85.</citation>
    <PMID>2573278</PMID>
  </reference>
  <reference>
    <citation>Hill SY, Armstrong J, Steinhauer SR, Baughman T, Zubin J. Static ataxia as a psychobiological marker for alcoholism. Alcohol Clin Exp Res. 1987 Aug;11(4):345-8.</citation>
    <PMID>3307504</PMID>
  </reference>
  <reference>
    <citation>Shigeta Y, Ishii H, Takagi S, Yoshitake Y, Hirano T, Takata H, Kohno H, Tsuchiya M. HLA antigens as immunogenetic markers of alcoholism and alcoholic liver disease. Pharmacol Biochem Behav. 1980;13 Suppl 1:89-94.</citation>
    <PMID>7243836</PMID>
  </reference>
  <reference>
    <citation>Smith SS, O'Hara BF, Persico AM, Gorelick DA, Newlin DB, Vlahov D, Solomon L, Pickens R, Uhl GR. Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry. 1992 Sep;49(9):723-7.</citation>
    <PMID>1355337</PMID>
  </reference>
  <reference>
    <citation>Uhl GR, Liu QR, Walther D, Hess J, Naiman D. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet. 2001 Dec;69(6):1290-300. Epub 2001 Nov 6.</citation>
    <PMID>11704927</PMID>
  </reference>
  <reference>
    <citation>Moolchan ET, Radzius A, Epstein DH, Uhl G, Gorelick DA, Cadet JL, Henningfield JE. The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav. 2002 Jan-Feb;27(1):101-13.</citation>
    <PMID>11800217</PMID>
  </reference>
  <reference>
    <citation>Uhl GR, Liu QR, Naiman D. Substance abuse vulnerability loci: converging genome scanning data. Trends Genet. 2002 Aug;18(8):420-5. Review.</citation>
    <PMID>12142011</PMID>
  </reference>
  <reference>
    <citation>Stein L, Belluzzi J. Second messengers, natural rewards, and drugs of abuse. Clin Neuropharmacol. 1986;9 Suppl 4:205-7.</citation>
    <PMID>3032425</PMID>
  </reference>
  <reference>
    <citation>Uhl GR, Gold LH, Risch N. Genetic analyses of complex behavioral disorders. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2785-6.</citation>
    <PMID>9096294</PMID>
  </reference>
  <reference>
    <citation>Uhl GR, Persico AM, Smith SS. Current excitement with D2 dopamine receptor gene alleles in substance abuse. Arch Gen Psychiatry. 1992 Feb;49(2):157-60.</citation>
    <PMID>1347991</PMID>
  </reference>
  <reference>
    <citation>Johnson EO, van den Bree MB, Uhl GR, Pickens RW. Indicators of genetic and environmental influences in drug abusing individuals. Drug Alcohol Depend. 1996 May;41(1):17-23.</citation>
    <PMID>8793306</PMID>
  </reference>
  <reference>
    <citation>Uhl GR. Molecular genetics of substance abuse vulnerability: a current approach. Neuropsychopharmacology. 1999 Jan;20(1):3-9. Review.</citation>
    <PMID>9885780</PMID>
  </reference>
  <reference>
    <citation>Wise RA. Action of drugs of abuse on brain reward systems. Pharmacol Biochem Behav. 1980;13 Suppl 1:213-23. Review.</citation>
    <PMID>6113601</PMID>
  </reference>
  <reference>
    <citation>Gelernter J, Moises H, Grandy D, et al. Exclusion of schizophrenia triat from regions of the D2 dopamine receptor and prophobilinogen deaminase genes. In: 28th Annual Meeting, American College of Neurophyschopharmacology, December 13, 1980; Maui, Hawaii, Abstracts p.216.</citation>
  </reference>
  <reference>
    <citation>Wyatt RJ, Farouk K, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatric Annals 1988; 18:531-534.</citation>
  </reference>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2005</study_first_submitted>
  <study_first_submitted_qc>October 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2005</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <keyword>Substance abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

